Revance Therapeutics Inc

Revance Therapeutics Inc

Health CarePharmaceuticals and Biotechnology
  • Price (USD)21.35
  • Today's Change-0.885 / -3.98%
  • Shares traded228.57k
  • 1 Year change-17.62%
  • Beta1.0608
Data delayed at least 15 minutes, as of Aug 19 2022 15:57 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Revance Therapeutics, Inc. is a commercial stage biotechnology company. The Company is focused on advanced aesthetic and therapeutic offerings, including neuromodulator product, DaxibotulinumtoxinA for Injection. The DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a purified botulinum toxin that does not contain human or animal-based components. The Company is also evaluating additional aesthetic and therapeutic indications for DaxibotulinumtoxinA for Injection including the full upper face, which includes glabellar lines, forehead lines and crow’s feet, and adult upper limb spasticity. It offers products and services for United States aesthetics practices, including the resilient hyaluronic acid (RHA) Collection of dermal fillers and OPUL. The RHA Collection of dermal fillers is a dermal filler for the correction of dynamic facial wrinkles and folds. OPUL’s product offering includes the point-of-sale platform, software and hardware terminal.

  • Revenue in USD (TTM)99.32m
  • Net income in USD-263.25m
  • Incorporated1999
  • Employees495.00
  • Location
    Revance Therapeutics Inc1222 Demonbreun Street, Suite 2000NASHVILLE 37203United StatesUSA
  • Phone+1 (615) 724-7755
  • Fax+1 (302) 674-5266
  • Websitehttps://www.revance.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
ImmunoGen, Inc.89.44m-160.68m1.16bn106.00--4.69--13.10-0.6907-0.69070.38371.130.2472--25.49843,792.40-44.40-35.82-62.24-48.56-----179.64-121.91---23.280.00---47.20---213.94------
Aclaris Therapeutics Inc6.14m-83.27m1.18bn75.00--4.78--183.48-1.33-1.330.09833.540.0217--7.7981,880.00-29.42-45.25-31.14-50.3827.1923.19-1,355.98-1,612.49----0.00--4.30---77.63--5.83--
Morphic Holding Inc75.30m-51.09m1.19bn101.00--3.31--17.05-1.43-1.432.0010.090.1765--64.08745,524.80-11.97---12.79-------67.85------0.00---55.96---112.32------
Merus NV52.72m-53.88m1.22bn121.00--3.70--22.91-1.30-1.301.267.120.1279--13.91435,677.70-13.07-24.71-15.40-29.16-----102.21-178.24----0.00--64.0077.6421.86--9.66--
Chinook Therapeutics Inc54.36m-92.48m1.23bn138.00--2.54--23.73-1.69-1.691.008.070.1077--30.35393,876.80-18.33-22.27-19.35-24.07-----170.15-441.76---20.800.00--6,142.440.3698-26.11---39.87--
Editas Medicine Inc31.80m-184.49m1.24bn264.00--2.74--40.10-2.70-2.700.46476.770.0476--60.92120,450.80-27.60-28.88-29.89-32.06-----580.16-368.55----0.00---71.8533.37-65.98--17.96--
Madrigal Pharmaceuticals Inc0.00-255.90m1.24bn71.00--15.10-----15.07-
Revance Therapeutics Inc99.32m-263.25m1.27bn495.00------15.80-3.84-3.841.45-0.0360.16523.3431.88200,654.50-43.77-50.56-49.33-56.2868.60---265.04-1,010.993.20-31.541.01--407.65203.930.2762--44.10--
Taro Pharmaceutical Industries Ltd.570.90m91.11m1.28bn1.46k14.220.755811.012.272.422.4215.1945.590.25191.372.37392,370.404.023.425.313.9952.0361.5115.9612.783.02----0.002.25-8.59115.07-33.7525.45--
USANA Health Sciences, Inc.1.08bn89.28m1.29bn1.98k15.203.2816.561.234.544.5454.9421.041.882.35--545,496.4015.5320.3420.6927.8681.0882.308.279.981.93----0.004.573.35-6.543.09-17.15--
Vericel Corp155.22m-16.45m1.29bn281.00--7.32--8.25-0.35-0.353.313.710.66513.654.75552,373.70-7.05-5.85-7.87-6.7466.0065.61-10.60-7.185.56--0.0004--25.7723.49-360.86--41.10--
Petro Usa Inc0.00-9.15k1.30bn-----------0.296-0.2960.00-3.60---------------------------40.59---------61.48------
Hims & Hers Health Inc320.88m-72.51m1.31bn398.00--4.28--4.40-0.3622-0.36221.611.590.88169.83100.20806,226.10-19.92---21.98--74.48---22.60--4.53--0.00-------3,430.95------
Syndax Pharmaceuticals Inc138.95m818.00k1.36bn59.00153.213.741,582.249.77-0.0331-0.03312.416.420.4151--19.932,355,102.000.2444-27.650.2663-30.65----0.5887-163.32--1.590.0529--9,109.56158.09132.34---13.15--
Exscientia PLC (ADR)-100.00bn-100.00bn1.37bn287.00--2.19----------5.57------------------------9.55--0.0125--182.87---120.94------
Medifast Inc1.66bn156.90m1.39bn984.009.5410.938.620.851813.4713.47142.7111.754.723.58--1,689,189.0044.5240.9986.5364.9172.7674.689.4410.780.4588462.020.172647.6163.2540.9359.4755.8664.0939.63
Data as of Aug 19 2022. Currency figures normalised to Revance Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

45.70%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 30 Jun 20224.81m6.60%
Palo Alto Investors LPas of 31 Mar 20224.42m6.07%
JPMorgan Investment Management, Inc.as of 30 Jun 20224.27m5.87%
GIC Pte Ltd. (Investment Management)as of 31 Dec 20214.18m5.74%
The Vanguard Group, Inc.as of 30 Jun 20223.53m4.85%
Capital Research & Management Co. (World Investors)as of 31 Mar 20223.35m4.60%
Polar Capital LLPas of 31 Mar 20222.46m3.38%
Franklin Advisers, Inc.as of 30 Jun 20222.33m3.21%
JPMorgan Asset Management (UK) Ltd.as of 30 Jun 20222.15m2.96%
Jennison Associates LLCas of 30 Jun 20221.76m2.41%
More ▼
Data from 31 Mar 2022 - 02 Aug 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.